62dc606be23ef9ec5a5702ad0f36f827 pmc_10093050.pdf 5e8c5464369d45b40194a87a70bcb058919699b3 pmc_10093050.pdf 2a327c26e8d0198b9b2bb9e76a0949341e6e6e415fbc62fcbb8cd9054a5a5385 pmc_10093050.pdf Title: Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs: Results from the RIETE Registry Subject: Background: The clinical characteristics and outcomes of cancer patients with lower-limb isolated superficial vein thrombosis (SVT) have not been consistently evaluated. Methods: We used data in the RIETE registry to compare the clinical characteristics and 90-day outcomes for patients with: (1) active cancer and lower-limb SVT; (2) active cancer and lower-limb deep vein thrombosis (DVT); (3) lower-limb SVT without cancer. The primary outcomes included subsequent symptomatic SVT, DVT or pulmonary embolism (PE). Secondary outcomes were major bleeding and death. Results: From March 2015 to April 2021, there were 110 patients with cancer and SVT, 1695 with cancer and DVT, and 1030 with SVT but no cancer. Most patients in all subgroups (93%, 99% and 96%, respectively) received anticoagulants, while those with SVT received lower daily doses of low-molecular-weight heparin (114 58, 163 44, and 106 50 IU/kg, respectively). During the first 90 days, 101 patients (3.6%) developed subsequent VTE (PE 47, DVT 41, SVT 13), whereas 72 (2.5%) had major bleeding and 282 (9.9%) died. Among the three groups, 90-day events were, respectively: VTE at rates of 7.3%, 4.0% and 2.4%; major bleeding at rates of 2.7%, 3.9% and 0.3%; mortality at rates of 8.2%, 16% and 0.3%. Between D90 and D180, only one SVT recurrence and one death occurred in SVT cancer patients. In multivariable analysis, cancer was associated with subsequent VTE (HR = 2.04; 1.15–3.62), while initial presentation as SVT or DVT were not associated with a different risk. Conclusions: The risk for subsequent VTE (including symptomatic SVT, DVT or PE) was similar in cancer patients with isolated SVT than in those with isolated DVT. Keywords: superficial vein thrombosis; deep venous thrombosis; cancers; anticoagulants; prognosis Author: Philippe Debourdeau, Laurent Bertoletti, Carme Font, Juan José López-Núñez, Covadonga Gómez-Cuervo, Isabelle Mahe, Remedios Otero-Candelera, Maria Dolores Adarraga, Patricia López-Miguel, Manuel Monreal and RIETE Investigators Creator: LaTeX with hyperref Producer: pdfTeX-1.40.21 CreationDate: Wed Mar 29 11:51:45 2023 CEST ModDate: Wed Mar 29 11:55:12 2023 CEST Tagged: no UserProperties: no Suspects: no Form: none JavaScript: no Pages: 10 Encrypted: no Page size: 595.276 x 841.89 pts (A4) Page rot: 0 File size: 452061 bytes Optimized: no PDF version: 1.7 name type encoding emb sub uni object ID ------------------------------------ ----------------- ---------------- --- --- --- --------- GJXIAY+VnURWPalladioL Type 1 Custom yes yes no 10 0 GELFEX+URWPalladioL-Bold Type 1 Custom yes yes no 15 0 POMVJY+URWPalladioL-Roma Type 1 Custom yes yes no 20 0 CQDVIF+URWPalladioL-Ital Type 1 Custom yes yes no 24 0 JGMOZW+CMSY10 Type 1 Builtin yes yes no 28 0 YAJGTT+VnURWPalladioL-Bold Type 1 Custom yes yes no 32 0 LCJEVJ+TimesNewRomanPS-BoldItalicMT Type 1C WinAnsi yes yes no 51 0 OVNEXW+EURM10 Type 1 Builtin yes yes no 79 0 VROGWP+URWPalladioL-BoldItal Type 1 Custom yes yes no 83 0 GEPEML+PalatinoLinotype,Bold TrueType WinAnsi yes yes no 109 0 GEPEMN+PalatinoLinotype TrueType WinAnsi yes yes no 112 0 GEPEMP+PalatinoLinotype,Italic TrueType WinAnsi yes yes no 115 0 GEPFJL+TimesNewRoman CID TrueType Identity-H yes yes yes 118 0 Jhove (Rel. 1.22.1, 2019-04-17) Date: 2023-08-10 02:25:59 CEST RepresentationInformation: pmc_10093050.pdf ReportingModule: PDF-hul, Rel. 1.12.1 (2019-04-17) LastModified: 2023-08-01 02:38:09 CEST Size: 452061 Format: PDF Version: 1.7 Status: Well-Formed and valid SignatureMatches: PDF-hul MIMEtype: application/pdf PDFMetadata: Objects: 243 FreeObjects: 1 IncrementalUpdates: 0 DocumentCatalog: PageLayout: SinglePage PageMode: UseNone Outlines: Item: Title: Introduction Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@44c8afef Item: Title: Methods Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@7b69c6ba Children: Item: Title: Data Source Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@46daef40 Item: Title: Inclusion Criteria Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@12f41634 Item: Title: Study Design Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@13c27452 Item: Title: Statistical Analysis Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@262b2c86 Item: Title: Results Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@371a67ec Children: Item: Title: Cancer Patients with SVT vs. Cancer Patients with DVT Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@5ed828d Item: Title: Cancer Patients with SVT vs. Non-Cancer Patients with SVT Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@50d0686 Item: Title: VTE Recurrence among the Whole Population Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@7a3d45bd Item: Title: Discussion Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@1e7c7811 Item: Title: Conclusions Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@77ec78b9 Item: Title: References Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@1a3869f4 Info: Title: Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs: Results from the RIETE Registry Author: Philippe Debourdeau, Laurent Bertoletti, Carme Font, Juan José López-Núñez, Covadonga Gómez-Cuervo, Isabelle Mahe, Remedios Otero-Candelera, Maria Dolores Adarraga, Patricia López-Miguel, Manuel Monreal and RIETE Investigators Subject: Background: The clinical characteristics and outcomes of cancer patients with lower-limb isolated superficial vein thrombosis (SVT) have not been consistently evaluated. Methods: We used data in the RIETE registry to compare the clinical characteristics and 90-day outcomes for patients with: (1) active cancer and lower-limb SVT; (2) active cancer and lower-limb deep vein thrombosis (DVT); (3) lower-limb SVT without cancer. The primary outcomes included subsequent symptomatic SVT, DVT or pulmonary embolism (PE). Secondary outcomes were major bleeding and death. Results: From March 2015 to April 2021, there were 110 patients with cancer and SVT, 1695 with cancer and DVT, and 1030 with SVT but no cancer. Most patients in all subgroups (93%, 99% and 96%, respectively) received anticoagulants, while those with SVT received lower daily doses of low-molecular-weight heparin (114 58, 163 44, and 106 50 IU/kg, respectively). During the first 90 days, 101 patients (3.6%) developed subsequent VTE (PE 47, DVT 41, SVT 13), whereas 72 (2.5%) had major bleeding and 282 (9.9%) died. Among the three groups, 90-day events were, respectively: VTE at rates of 7.3%, 4.0% and 2.4%; major bleeding at rates of 2.7%, 3.9% and 0.3%; mortality at rates of 8.2%, 16% and 0.3%. Between D90 and D180, only one SVT recurrence and one death occurred in SVT cancer patients. In multivariable analysis, cancer was associated with subsequent VTE (HR = 2.04; 1.15 3.62), while initial presentation as SVT or DVT were not associated with a different risk. Conclusions: The risk for subsequent VTE (including symptomatic SVT, DVT or PE) was similar in cancer patients with isolated SVT than in those with isolated DVT. Keywords: superficial vein thrombosis; deep venous thrombosis; cancers; anticoagulants; prognosis Creator: LaTeX with hyperref Producer: pdfTeX-1.40.21 CreationDate: Wed Mar 29 11:51:45 CEST 2023 ModDate: Wed Mar 29 11:55:12 CEST 2023 ID: 0xf30956a59a500e810e2ce444b3f6d574, 0xf30956a59a500e810e2ce444b3f6d574 Filters: FilterPipeline: FlateDecode Fonts: Type1: Font: BaseFont: YAJGTT+VnURWPalladioL-Bold FontSubset: true FirstChar: 178 LastChar: 243 FontDescriptor: FontName: YAJGTT+VnURWPalladioL-Bold Flags: Symbolic FontBBox: -152, -301, 1000, 935 FontFile: true EncodingDictionary: Differences: true Font: BaseFont: VROGWP+URWPalladioL-BoldItal FontSubset: true FirstChar: 44 LastChar: 150 FontDescriptor: FontName: VROGWP+URWPalladioL-BoldItal Flags: Symbolic FontBBox: -170, -300, 1073, 935 FontFile: true EncodingDictionary: Differences: true Font: BaseFont: POMVJY+URWPalladioL-Roma FontSubset: true FirstChar: 2 LastChar: 250 FontDescriptor: FontName: POMVJY+URWPalladioL-Roma Flags: Symbolic FontBBox: -166, -283, 1021, 943 FontFile: true EncodingDictionary: Differences: true Font: BaseFont: CQDVIF+URWPalladioL-Ital FontSubset: true FirstChar: 39 LastChar: 121 FontDescriptor: FontName: CQDVIF+URWPalladioL-Ital Flags: Symbolic FontBBox: -170, -305, 1010, 941 FontFile: true EncodingDictionary: Differences: true Font: BaseFont: GJXIAY+VnURWPalladioL FontSubset: true FirstChar: 146 LastChar: 230 FontDescriptor: FontName: GJXIAY+VnURWPalladioL Flags: Symbolic FontBBox: -166, -283, 1021, 943 FontFile: true EncodingDictionary: Differences: true Font: BaseFont: JGMOZW+CMSY10 FontSubset: true FirstChar: 6 LastChar: 21 FontDescriptor: FontName: JGMOZW+CMSY10 Flags: Symbolic FontBBox: -29, -960, 1116, 775 FontFile: true Font: BaseFont: GELFEX+URWPalladioL-Bold FontSubset: true FirstChar: 2 LastChar: 241 FontDescriptor: FontName: GELFEX+URWPalladioL-Bold Flags: Symbolic FontBBox: -152, -301, 1000, 935 FontFile: true EncodingDictionary: Differences: true Font: BaseFont: OVNEXW+EURM10 FontSubset: true FirstChar: 22 LastChar: 22 FontDescriptor: FontName: OVNEXW+EURM10 Flags: Symbolic FontBBox: -32, -243, 1060, 720 FontFile: true Pages: Page: Sequence: 1 Annotations: Annotation: Subtype: Link Rect: 106, 279, 152, 288 Annotation: Subtype: Link Rect: 34, 267, 140, 276 Annotation: Subtype: Link Rect: 34, 164, 96, 186 Annotation: Subtype: Link Rect: 126, 90, 154, 99 Annotation: Subtype: Link Rect: 34, 78, 147, 87 Annotation: Subtype: Link Rect: 34, 756, 152, 792 Annotation: Subtype: Link Rect: 515, 756, 560, 792 Annotation: Subtype: Link Rect: 428, 642, 439, 655 Annotation: Subtype: Link Rect: 240, 629, 251, 643 Annotation: Subtype: Link Rect: 385, 629, 396, 643 Annotation: Subtype: Link Rect: 146, 616, 157, 630 Annotation: Subtype: Link Rect: 114, 17, 265, 28 Annotation: Subtype: Link Rect: 410, 17, 560, 28 Annotation: Subtype: Link Rect: 34, 400, 87, 419 Page: Sequence: 2 Annotations: Annotation: Subtype: Link Rect: 204, 607, 211, 616 ActionDest: 99 Annotation: Subtype: Link Rect: 200, 582, 207, 591 ActionDest: 99 Annotation: Subtype: Link Rect: 527, 569, 534, 578 ActionDest: 99 Annotation: Subtype: Link Rect: 240, 532, 247, 541 ActionDest: 99 Annotation: Subtype: Link Rect: 248, 531, 255, 541 ActionDest: 99 Annotation: Subtype: Link Rect: 400, 519, 407, 528 ActionDest: 99 Annotation: Subtype: Link Rect: 445, 506, 452, 515 ActionDest: 125 Annotation: Subtype: Link Rect: 452, 506, 459, 515 ActionDest: 125 Annotation: Subtype: Link Rect: 541, 456, 548, 465 ActionDest: 125 Annotation: Subtype: Link Rect: 549, 456, 556, 465 ActionDest: 125 Annotation: Subtype: Link Rect: 326, 304, 333, 313 ActionDest: 125 Annotation: Subtype: Link Rect: 378, 191, 385, 200 ActionDest: 125 Page: Sequence: 3 Annotations: Annotation: Subtype: Link Rect: 269, 610, 276, 619 ActionDest: 125 Annotation: Subtype: Link Rect: 465, 471, 472, 481 ActionDest: 125 Annotation: Subtype: Link Rect: 225, 446, 232, 455 ActionDest: 125 Annotation: Subtype: Link Rect: 417, 218, 424, 229 ActionDest: 76 Annotation: Subtype: Link Rect: 472, 154, 479, 166 ActionDest: 76 Annotation: Subtype: Link Rect: 225, 116, 232, 128 ActionDest: 76 Annotation: Subtype: Link Rect: 476, 79, 483, 91 ActionDest: 87 Page: Sequence: 4 Page: Sequence: 5 Page: Sequence: 6 Annotations: Annotation: Subtype: Link Rect: 507, 720, 514, 732 ActionDest: 90 Annotation: Subtype: Link Rect: 521, 405, 528, 417 ActionDest: 76 Annotation: Subtype: Link Rect: 470, 380, 477, 392 ActionDest: 87 Annotation: Subtype: Link Rect: 505, 317, 512, 329 ActionDest: 90 Annotation: Subtype: Link Rect: 375, 166, 382, 178 ActionDest: 93 Page: Sequence: 7 Annotations: Annotation: Subtype: Link Rect: 199, 313, 206, 322 ActionDest: 99 Annotation: Subtype: Link Rect: 261, 162, 268, 171 ActionDest: 125 Annotation: Subtype: Link Rect: 528, 149, 540, 158 ActionDest: 125 Annotation: Subtype: Link Rect: 543, 149, 555, 158 ActionDest: 125 Annotation: Subtype: Link Rect: 286, 137, 298, 146 ActionDest: 125 Annotation: Subtype: Link Rect: 301, 137, 313, 146 ActionDest: 125 Annotation: Subtype: Link Rect: 216, 99, 228, 108 ActionDest: 125 Annotation: Subtype: Link Rect: 229, 99, 240, 108 ActionDest: 125 Page: Sequence: 8 Annotations: Annotation: Subtype: Link Rect: 189, 673, 196, 682 ActionDest: 99 Annotation: Subtype: Link Rect: 292, 660, 299, 669 ActionDest: 125 Annotation: Subtype: Link Rect: 470, 647, 477, 657 ActionDest: 125 Annotation: Subtype: Link Rect: 303, 522, 310, 531 ActionDest: 99 Annotation: Subtype: Link Rect: 441, 522, 448, 531 ActionDest: 99 Annotation: Subtype: Link Rect: 448, 522, 455, 531 ActionDest: 125 Annotation: Subtype: Link Rect: 456, 522, 468, 531 ActionDest: 125 Annotation: Subtype: Link Rect: 468, 522, 480, 531 ActionDest: 125 Annotation: Subtype: Link Rect: 192, 497, 204, 506 ActionDest: 125 Annotation: Subtype: Link Rect: 549, 268, 556, 280 ActionDest: 99 Page: Sequence: 9 Annotations: Annotation: Subtype: Link Rect: 536, 392, 560, 403 Annotation: Subtype: Link Rect: 165, 380, 390, 391 Annotation: Subtype: Link Rect: 399, 118, 436, 129 Annotation: Subtype: Link Rect: 443, 118, 479, 129 Annotation: Subtype: Link Rect: 122, 96, 159, 106 Annotation: Subtype: Link Rect: 165, 96, 201, 106 Annotation: Subtype: Link Rect: 177, 61, 214, 71 Annotation: Subtype: Link Rect: 220, 61, 256, 71 Page: Sequence: 10 Annotations: Annotation: Subtype: Link Rect: 104, 711, 141, 721 Annotation: Subtype: Link Rect: 147, 711, 183, 721 Annotation: Subtype: Link Rect: 153, 676, 191, 687 Annotation: Subtype: Link Rect: 197, 676, 233, 687 Annotation: Subtype: Link Rect: 95, 642, 133, 652 Annotation: Subtype: Link Rect: 139, 642, 175, 652 Annotation: Subtype: Link Rect: 241, 607, 279, 617 Annotation: Subtype: Link Rect: 285, 607, 321, 617 Annotation: Subtype: Link Rect: 450, 595, 560, 606 Annotation: Subtype: Link Rect: 56, 583, 401, 594 Annotation: Subtype: Link Rect: 104, 550, 141, 560 Annotation: Subtype: Link Rect: 147, 550, 183, 560 Annotation: Subtype: Link Rect: 442, 514, 480, 525 Annotation: Subtype: Link Rect: 486, 514, 522, 525 Annotation: Subtype: Link Rect: 438, 491, 476, 502 Annotation: Subtype: Link Rect: 482, 491, 518, 502 Annotation: Subtype: Link Rect: 213, 457, 249, 468 Annotation: Subtype: Link Rect: 304, 434, 341, 445 Annotation: Subtype: Link Rect: 347, 434, 383, 445 Annotation: Subtype: Link Rect: 462, 411, 500, 422 Annotation: Subtype: Link Rect: 506, 411, 542, 422 Annotation: Subtype: Link Rect: 279, 388, 317, 399 Annotation: Subtype: Link Rect: 323, 388, 359, 399 Annotation: Subtype: Link Rect: 216, 354, 254, 364 Annotation: Subtype: Link Rect: 260, 354, 296, 364 Annotation: Subtype: Link Rect: 59, 308, 96, 318 Annotation: Subtype: Link Rect: 102, 308, 138, 318 Annotation: Subtype: Link Rect: 442, 284, 480, 295 Annotation: Subtype: Link Rect: 486, 284, 522, 295 Annotation: Subtype: Link Rect: 157, 273, 421, 284 Annotation: Subtype: Link Rect: 158, 227, 196, 238 Annotation: Subtype: Link Rect: 202, 227, 238, 238 Annotation: Subtype: Link Rect: 362, 204, 400, 215 Annotation: Subtype: Link Rect: 406, 204, 442, 215 Annotation: Subtype: Link Rect: 185, 170, 222, 180 Annotation: Subtype: Link Rect: 229, 170, 265, 180 Checksum: 7d495a08 Type: CRC32 Checksum: 62dc606be23ef9ec5a5702ad0f36f827 Type: MD5 Checksum: 5e8c5464369d45b40194a87a70bcb058919699b3 Type: SHA-1